Ashok Jagani, MD
Infectious Disease · Northport, ALNPI 1447205950
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.4% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Viiv Healthcare Company accounts for 67.8% of it on its own, with 11 other manufacturers making up the rest.
Across 97 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$1K
- AbbVie$124
- Janssen Products, LP$80
- Johnson & Johnson$72
- Merck$59
- Paratek Pharmaceuticals, Inc.$54
- plus $138 from 6 others
What the payments were for
- Food & beverage$1,52793%
- Education$1087%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 69 | $1,108 |
| AbbVie(2 entities) | 9 | $124 |
| Janssen Products, LP | 1 | $80 |
| Johnson & Johnson(2 entities) | 4 | $72 |
| Merck | 3 | $59 |
| Paratek Pharmaceuticals, Inc. | 3 | $54 |
| Gilead | 2 | $36 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $28 |
| Insmed, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Melinta Therapeutics, LLC | 1 | $16 |
| La Jolla Pharmaceutical Company | 1 | $14 |
How this compares
$1,635 in reported general payments places this provider in the 55th percentile of 104 infectious disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 19 | $87,707 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 20 | $76,490 |
| Daptomycin | 47 | $69,240 |
| DovatoDolutegravir Sodium/Lamivudine | 15 | $56,247 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $25,899 |
| CeftriaxoneCeftriaxone Sodium | 61 | $12,966 |
| Minocycline Hcl | 18 | $891 |
| Amoxicillin | 12 | $523 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $510 |
| Hydralazine Hcl | 13 | $383 |
| Sodium Chloride0.9 % Sodium Chloride | 48 | $378 |
| Doxycycline Hyclate | 11 | $247 |
| Azithromycin | 14 | $199 |
| Prednisone | 27 | $147 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 25 | $132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadGenvoya, Descovy | $36 | $102,38932 claims |
| Janssen Products, LPSymtuza | $80 | $87,70719 claims |
| Viiv Healthcare CompanyDovato | $1,108 | $56,24715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 104 infectious disease providers in Alabama.
Other infectious disease in Northport
- Ali HassounHuntsville$262K
- John BaddleyBirmingham$113K
- Christina MuznyBirmingham$111K
- Carlos Reyes-SacinMontgomery$97K
- April TruettMontgomery$85K
- Sonya HeathBirmingham$80K
- William GeislerBirmingham$63K
- Edward HookBirmingham$61K
- Edgar OvertonBirmingham$46K
- Jane SchwebkeBirmingham$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.